TELMISARTAN-D3

Telmisartan-d₃ is intended for use as an internal standard for the quantification of telmisartan by GC- or LC-MS. Telmisartan is a nonpeptide angiotensin (AT) II receptor antagonist which selectively and insurmountably inhibits the AT II receptor subtype AT₁ (K_i = 3.7 nM). It also acts as a partial agonist of peroxisome proliferator-activated receptor gamma (PPARγ), activating the receptor to 25-30% of that produced by the full agonist rosiglitazone (; EC₅₀ = 4.5 μM). Through these actions, telmisartan potently reduces blood pressure in various animal models of hypertension, diminishing cardiac hypertrophy, cardiovascular and renal risk, and glomerulosclerosis.

Off-White Crystalline Solid

Labelled Telmisartan, an angiotensin II receptor antagonist

TelMisartan-d3 can be intended for use as an internal standard for the quantification of Telmisartan by GC- or LC-mass spectrometry.

TelMisartan-d3 is an angiotensin II receptor antagonist.

[1] W. WIENEN. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277[J]. British Journal of Pharmacology, 1993, 110 1: 245-252. DOI: 10.1111/j.1476-5381.1993.tb13800.x
[2] STEPHEN C BENSON. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.[J]. Hypertension, 2004, 43 5: 993-1002. DOI: 10.1161/01.hyp.0000123072.34629.57
[3] ARONOW W S. Telmisartan[J]. Drugs, 2012, 56 1: 1045. DOI: 10.2165/00003495-199856060-00009
[4] JUGDUTT B I. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.[J]. Clinical Interventions in Aging, 2010, 5: 403-416. DOI: 10.2147/cia.s6709
[5] ROLAND E SCHMIEDER  Matthew R W  George Bakris. Telmisartan in incipient and overt diabetic renal disease.[J]. Journal of Nephrology, 2011, 24 3: 263-273. DOI: 10.5301/jn.2011.6416